Advertisement

Picture Wirtschaftsförderung Sachsen Life Sciences in Saxony 650x100px
Collaboration › Details

Voyager Therapeutics–Touchlight: dbDNA technology, 202211– license €na to use dbDNA technology in creation of novel capsids

 

Period Period 2022-11-15
Organisations Partner, 1st Voyager Therapeutics Inc. (Nasdaq: VYGR)
  Partner, 2nd Touchlight (Group)
Products Product dbDNA™ (doggybone DNA)
  Product 2 gene therapy
     

Touchlight Genetics Ltd.. (11/15/22). "Press Release: Touchlight Signs License Agreement with Voyager for Use of Touchlight’s DNA Technology in Voyager’s Capsid Discovery Platform". Hampton.

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids.

Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in the creation of novel capsids with the potential to power programs in Voyager’s pipeline and supporting Voyager alliances with leading biopharma partners.

Touchlight’s enzymatically amplified doggybone DNA technology enables the rapid and scalable amplification of DNA regardless of sequence length or complexity and is being deployed across genetic medicine applications including mRNA, AAV, lentivirus, genome editing and DNA vaccines. doggybone DNA is amplified in vitro, avoiding the constraints of using cells for DNA amplification, thus also enabling applications such as the production of high-diversity DNA libraries.

Karen Fallen, Group CEO of Touchlight, commented: “Today’s announcement is another example of the power and breadth of application of the doggybone DNA platform. We’re delighted that the platform is being utilised to contribute to the advancement of novel gene therapies for diseases of high unmet medical need.”

Financial terms are not disclosed.


- ENDS -


About Touchlight

Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as doggybone DNA” or dbDNA™.

dbDNA is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.

Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.

Issued for and on behalf of Touchlight by Instinctif Partners.


For more information please contact:

Karen Fallen, Chief Executive Officer
Robin Bodicoat, Head of Marketing
E: info@touchlight.com
T: +44 20 8481 9200

Agnes Stephens
E: touchlight@instinctif.com
T: +44 20 7457 2020

   
Record changed: 2022-12-02

Advertisement

Picture Wirtschaftsförderung Sachsen Life Sciences in Saxony 650x200px

More documents for Voyager Therapeutics Inc. (Nasdaq: VYGR)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Whitepaper State of Innovation in Europe 650x300px




» top